Edition:
United States

Blueprint Medicines Q3 loss per share $0.96


Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines reports third quarter 2017 financial results.Q3 loss per share $0.96.Q3 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Blueprint Medicines - ‍existing cash will be sufficient to fund its operating expenses and capex requirements into H2 2019​.Blueprint Medicines - ‍plans to initiate a global, pivotal Phase 3 clinical trial of BLU-285 in third-line patients with KIT-driven GIST in H1 2018​. 

Company Quote

58.51
1.04 +1.81%
1:43pm EST